Skip to main content

Advertisement

Table 2 Quality of included trials.

From: Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

Study Adequate sequence generation Allocation concealment Blinding Incomplete outcome data addressed Percentage who completed the trial Free of selective reporting Groups comparable at baseline Sample size calculation
Rosenstock 2009[23] Unclear Unclear Yes, Double blind Yes Albi 30 mg QW/Albi 30 mg every two weeks/P: 71.0/75.0/78.4 Yes Yes Yes
Apovian 2010[43] Yes Yes Yes, Double blind Yes Exe/P: 72.2/72.7 Yes Yes Yes
Bergenstal 2009[28] Yes Yes No, Open label Yes Exe/BIAsp QD/BIAsp BID: 70.2/83.9/80.6 Yes Yes Yes
Bergenstal 2010[37] Yes Yes Yes, Double blind Yes Exe/Sita/Pio: 79.4/86.7/79.4 Yes Yes Yes
Bunck 2009[29] Yes Unclear Unclear Yes Exe/Glar: 83.3/90.9 Yes Yes Yes
Davies 2009 (HEELA)[30] Yes Unclear No, Open label Yes Exe/Glar: 83.9/88.9 Yes Yes Yes
Davis 2007[31] Unclear Unclear No, Open label Yes Exe/Ins: 57.6/93.8 Yes Yes Yes
DeFronzo 2005[42] Unclear Unclear Yes, Triple blind Yes Exe/P: 82.3/78.8 Yes Yes Yes
DeFronzo 2010[22] Yes Unclear No, Open label Yes Exe/Rosi: 73.3/75.6 Yes Yes No
Derosa 2010[27] Yes Yes No, Single blind Yes Exe/Glib: 93.7/87.7 Yes Yes No
Diamant 2010[34] Yes Yes No, Open label Yes Exe/Glar: 89.7/93.7 Yes Yes Yes
Drucker 2008[41] Unclear Unclear No, Open label Yes Exe/Exe lar: 88.4/86.5 Yes Yes Yes
Gao 2009[45] Yes Yes Yes, Double blind Yes Exe/P: 81.1/88.9 Yes Yes Yes
Gill 2010[26] Unclear Unclear Yes, Double blind Yes Exe/P: 78.6/88.5 Yes Yes Yes
Heine 2005[32] Yes Yes No, Open label Yes Exe/Glar: 80.9/90.6 Yes Yes Yes
Kadowaki 2009[20] Unclear Unclear Yes, Double blind Yes Exe/P: 83.8/97.5 Yes Yes Yes
Kendall 2005[21] Unclear Unclear Yes, Double blind Yes Exe/P: 82.6/76.1 Yes Yes Yes
Nauck 2007[33] Yes Yes Unclear Yes Exe/BIAsp 30 BID: 78.7/89.9 Yes Yes Yes
Zinman 2007[67] Yes Yes Yes, Double blind Yes Exe/P: 71.1/85.7 Yes Yes Yes
Kaku 2010[18] Unclear Unclear Yes, Double blind Yes Lir 0.6/Lir 0.9/P: 94.3/95.5/84.1 Yes Yes Unclear
Pratley 2010[38] Yes Yes No, Open label Yes Lir 1.2/Lir 1.8/Sita: 75.1/86.4/88.6 Yes Yes Yes
Marre 2009 (LEAD-1)[39] Unclear Unclear Yes, Double blind Yes Lir 1.2/Lir 1.8/Rosi/P: 86.0/91.0/83.6/72.8 Yes Yes Yes
Nauck 2009 (LEAD-2)[36] Yes Yes Yes, Double blind Yes Lir 1.2/Lir 1.8/Glim/P: 82.1/78.9/86.8/61.2 Yes Yes Yes
Zinman 2009 (LEAD-4)[44] Yes Yes Yes, Double blind Yes Lir 1.2/Lir 1.8/P: 86.0/74.7/68.4 Yes Yes Yes
Russell-Jones 2009 (LEAD-5)[35] Yes Yes Unclear Yes Lir 1.8/Glar/P: 90.0/94.4/84.2 Yes Yes Yes
Buse 2009 (LEAD-6)[40] Unclear Yes No, Open label Yes Lir 1.8/Exe: 86.7/81.0 Yes Yes Yes
Nauck 2009[24] Yes Yes Yes, Double blind Yes Tas 10 mg QW/Tas 20 mg QW/Tas 20 mg every two weeks/P: 91.8/88.0/93.9/95.9 Yes Yes Yes
Ratner 2010[25] Yes Unclear Yes, Double blind Yes Tas 20 mg QW/Tas 30 mg QW/Tas 40 mg QW: 90.6/81.8/81.3/96.9 Yes Yes No
  1. Albi: Albiglutide; Exe: Exenatide; Exe lar: long acting exenatide; Lir: Liraglutide; Tas: Taspoglutide; BIAsp: Biphasic insulin aspart; Glar: Insulin glargine; Ins: Insulin; Glib: Glibenclamide; Glim: Glimepiride; Pio: Pioglitazone; Rosi: Rosiglitazone; Sita: Sitagliptin; P: Placebo; BID: Twice daily; QD: Once daily; QW: Once weekly; HEELA: Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin; LEAD: Liraglutide Effect and Action in Diabetes